mRNA Therapeutics Market Set To Grow From $37.17 Billion In 2026 To $42.31 Billion By 2030 At A CAGR Of 3.3%
Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
mRNA Therapeutics Market Size Outlook: How Fast Will Revenue Grow Through 2030?
The mRNA therapeutics market has experienced steady expansion in recent years, with projections indicating an increase from $35.9 billion in 2025 to $37.18 billion in 2026, reflecting a compound annual growth rate (CAGR) of 3.6%. This historical growth has been driven by several key factors, including the groundbreaking success of mRNA vaccines against infectious diseases, significant progress in nucleic acid delivery technologies, a deeper comprehension of gene expression regulation, early-stage research confirming mRNA-driven protein synthesis, and substantial public investment in mRNA research platforms.
The mrna therapeutics market is projected to experience consistent expansion over the coming years. By 2030, its value is anticipated to reach $42.32 billion, reflecting a compound annual growth rate (CAGR) of 3.3%. This projected growth during the forecast period is driven by several factors, including the increasing demand for targeted and personalized treatment approaches, the broadening application of mrna technology in oncology and rare disease management, heightened biopharmaceutical investment in mrna development programs, a growing number of mrna-based drugs entering clinical trials, and the formation of strategic alliances between biotechnology companies and research institutions. Key trends shaping the forecast period involve the expansion of mrna technology beyond vaccines, a heightened emphasis on protein replacement therapies utilizing mrna, a growing clinical pipeline for non-vaccine mrna applications, increased funding for lipid nanoparticle delivery platforms, and the acceleration of comprehensive end-to-end mrna manufacturing capabilities.
Download A Free Sample Report For Comprehensive Market Insights:
mRNA Therapeutics Market Growth Factors Supporting Long-Term Expansion
The anticipated expansion of the mRNA therapeutics market is driven by the growing incidence of chronic and infectious diseases. These conditions, including tuberculosis, HIV/AIDS, and hepatitis, are characterized by their long duration and ability to transmit between individuals. Their rising prevalence is fueled by heightened global travel and deficiencies in healthcare systems, which amplify transmission rates and complicate effective control. mRNA therapeutics enable faster disease management by allowing the body to rapidly produce proteins that strengthen immune responses, facilitating the swift development of targeted vaccines and treatments. For example, in March 2024, the Centers for Disease Control and Prevention, a U.S. federal agency, reported that tuberculosis cases climbed from 8,320 in 2022 to 9,615 in 2023—an increase of 1,295 cases. As a result, the escalating prevalence of chronic and communicable diseases is accelerating the growth trajectory of the mRNA therapeutics market.
mRNA Therapeutics Market Segments: Where Are The Largest Growth Opportunities?
The mrna therapeutics market covered in this report is segmented –
1) By Product: Vaccines, Drugs
2) By Application: Infectious Diseases, Oncology, Rare Genetic Diseases, Respiratory Diseases, Other Applications
3) By End Use: Hospitals And Clinics, Research Organizations, Other End Uses
Subsegments:
1) By Vaccines: Infectious Disease Vaccines, Cancer Vaccines, Other Therapeutic Vaccines
2) By Drugs: Oncology Drugs, Cardiovascular Drugs, Autoimmune Disease Drugs, Other mRNA-Based Drugs
mRNA Therapeutics Market Industry Trends Shaping Future Revenue Growth
Leading players in the mRNA therapeutics space are channeling efforts into creating advanced treatments, particularly personalized neoantigen vaccines, designed to boost immune activity and elevate survival rates for cancer patients. These vaccines represent customized cancer therapies that leverage each individual’s distinct tumor-specific mutations, prompting the immune system to seek out and eliminate cancer cells. A notable example occurred in July 2023, when Merck & Co., Inc., a U.S.-based research-focused biopharmaceutical firm, collaborated with Moderna Therapeutics, Inc., a U.S.-based biotechnology company, to launch a Phase 3 randomized clinical trial (V940-001). This trial is investigating mRNA-4157 (V940) paired with KEYTRUDA® (pembrolizumab) as an adjuvant therapy for individuals with resected high-risk melanoma (Stage IIB-IV). This initiative builds on encouraging outcomes from the Phase 2b KEYNOTE-942/mRNA-4157-P201 trial, where the combination demonstrated a significant advantage over KEYTRUDA alone by lowering the likelihood of recurrence and distant metastasis. The Phase 3 study seeks to validate these results through primary and secondary endpoints focused on relapse-free survival and distant metastasis-free survival.
mRNA Therapeutics Market Major Participants And Competitive Dynamics
Major companies operating in the mrna therapeutics market are Pfizer Inc., Novartis AG, Sanofi AG, AstraZeneca plc, GlaxoSmithKline plc, Hoffmann-La Roche AG, Moderna Therapeutics Inc, BioNTech SE, Vertex Pharmaceuticals Incorporated, Catalent Inc, Alnylam Pharmaceuticals Inc, Sarepta Therapeutics Inc, Arcturus Therapeutics Holdings Inc, CureVac N.V, Ethris GMBH, eTheRNA immunotherapies NV, In-Cell-Art S.A.S., Nutcracker Therapeutics Inc, SCM LifeScience Co Ltd, Suzhou Abogen Biosciences Co Ltd, Tiba Biotech LLC, CSPC Pharmaceutical Group, CRISPR Therapeutics AG
Access The Complete mRNA Therapeutics Market Report:
mRNA Therapeutics Market Regional Distribution: Which Areas Drive Market Expansion?
North America was the largest region in the mRNA therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the mrna therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
